Fedratinib, a Janus kinase 2 (JAK2) inhibitor used as an anticancer drug, inhibits crucial intestinal thiamine transporter THTR2 and contributes to the development of Wernicke ́s encephalopathy [280]. The gene discussed is JAK2; the disease is Wernicke encephalopathy.